Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1988 1
1990 2
1991 3
1992 1
1993 1
1994 1
1995 2
1996 1
2000 4
2001 5
2002 2
2003 1
2005 2
2006 2
2008 1
2009 1
2010 1
2012 2
2013 1
2015 1
2016 3
2017 1
2018 3
2019 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
Impact of Type II LRRK2 inhibitors on signaling and mitophagy.
Tasegian A, Singh F, Ganley IG, Reith AD, Alessi DR. Tasegian A, et al. Among authors: reith ad. Biochem J. 2021 Oct 15;478(19):3555-3573. doi: 10.1042/BCJ20210375. Biochem J. 2021. PMID: 34515301 Free PMC article.
Molecular basis of mouse developmental mutants.
Reith AD, Bernstein A. Reith AD, et al. Genes Dev. 1991 Jul;5(7):1115-23. doi: 10.1101/gad.5.7.1115. Genes Dev. 1991. PMID: 2065969 Free article. Review. No abstract available.
Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.
Ding X, Stasi LP, Ho MH, Zhao B, Wang H, Long K, Xu Q, Sang Y, Sun C, Hu H, Yu H, Wan Z, Wang L, Edge C, Liu Q, Li Y, Dong K, Guan X, Tattersall FD, Reith AD, Ren F. Ding X, et al. Among authors: reith ad. Bioorg Med Chem Lett. 2018 May 15;28(9):1615-1620. doi: 10.1016/j.bmcl.2018.03.045. Epub 2018 Mar 19. Bioorg Med Chem Lett. 2018. PMID: 29588215
LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages.
Härtlova A, Herbst S, Peltier J, Rodgers A, Bilkei-Gorzo O, Fearns A, Dill BD, Lee H, Flynn R, Cowley SA, Davies P, Lewis PA, Ganley IG, Martinez J, Alessi DR, Reith AD, Trost M, Gutierrez MG. Härtlova A, et al. Among authors: reith ad. EMBO J. 2018 Jun 15;37(12):e98694. doi: 10.15252/embj.201798694. Epub 2018 May 22. EMBO J. 2018. PMID: 29789389 Free PMC article.
5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy.
Ding X, Stasi LP, Dai X, Long K, Peng C, Zhao B, Wang H, Sun C, Hu H, Wan Z, Jandu KS, Philps OJ, Chen Y, Wang L, Liu Q, Edge C, Li Y, Dong K, Guan X, Tattersall FD, Reith AD, Ren F. Ding X, et al. Among authors: reith ad. Bioorg Med Chem Lett. 2019 Jan 15;29(2):212-215. doi: 10.1016/j.bmcl.2018.11.054. Epub 2018 Nov 28. Bioorg Med Chem Lett. 2019. PMID: 30522952
Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors.
Ding X, Dai X, Long K, Peng C, Andreotti D, Bamborough P, Eatherton AJ, Edge C, Jandu KS, Nichols PL, Philps OJ, Stasi LP, Wan Z, Xiang JN, Dong K, Dossang P, Ho MH, Li Y, Mensah L, Guan X, Reith AD, Ren F. Ding X, et al. Among authors: reith ad. Bioorg Med Chem Lett. 2017 Sep 1;27(17):4034-4038. doi: 10.1016/j.bmcl.2017.07.052. Epub 2017 Jul 21. Bioorg Med Chem Lett. 2017. PMID: 28774425
43 results